Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 7Colorectal Neoplasms 4Colonic Neoplasms 2Anus Neoplasms 2Adenomatous Polyposis Coli 2Signs and Symptoms, Digestive 1Neoplasms 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1HIV Infections 1Colorectal Adenoma 1Anal Canal Carcinoma 1

Interventions

Fluorouracil 26Radiotherapy 18Mitomycin 17Cisplatin 12Capecitabine 12pembrolizumab 10Magnetic Resonance Spectroscopy 9Cyclophosphamide 9Radiation 8Paclitaxel 8Biopsy 8fludarabine 7Specimen Handling 7Nivolumab 7Drug Therapy 7Carboplatin 7Surveys and Questionnaires 6Cetuximab 6Papillomavirus Vaccines 5dehydroftorafur 4aldesleukin 4Vaccines 4Radiotherapy, Intensity-Modulated 4Observation 4Irinotecan 4Watchful Waiting 3Taxes 3Oxaliplatin 3Light Coagulation 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anus Neoplasms × Sigmoidoscopy × Clear all
NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡